Neovasc Inc. (NASDAQ:NVCN) (TSX: NVCN) CEO Fred Colen sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The Vancouver, Canada-based company develops, manufactures and markets medical device products for the cardiovascular marketplace. Its products include the Reducer, for the treatment of refractory angina.
Neovasc filing for a CE mark approval in Europe in 2020
Quick facts: Neovasc
Price: 4.2 CAD
Market Cap: $46.76 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE